|Drug class||Calcitonin gene-related peptide receptor antagonist|
|Main uses||Migraine attacks|
|Side effects||Nausea, tiredness, dry mouth|
|Interactions||CYP3A4 inhibitors or inducers|
|Typical dose||50 to 100 mg|
|Chemical and physical data|
|Molar mass||549.554 g·mol−1|
|3D model (JSmol)|
Ubrogepant, sold under the brand name Ubrelvy, is a medication used to treat migraine attacks. This includes whether or not an aura was present. It is not used for migraine prevention. It is taken by mouth.
Common side effects include nausea, tiredness and dry mouth. Safety during pregnancy or breastfeeding is unclear. Use is not recommended together with strong CYP3A4 inhibitors or inducers. It is a small-molecule calcitonin gene-related peptide receptor antagonist.
Ubrogepant was approved for medical use in the United States in 2019. In the United States it costs about 87 USD per 100 mg tablet as of 2021. It has not been approved in Europe as of 2021.
Ubrogepant is use to treat migraine attacks.
It is taken at a dose of 50 to 100 mg which may be repeated after more than 2 hours to a maximum of 200 mg per day.
The effectiveness of ubrogepant for the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials. In these studies, 1,439 adult patients with a history of migraine, with and without aura, received the approved doses of ubrogepant to treat an ongoing migraine. In both studies, the percentages of patients achieving pain freedom two hours after treatment (defined as a reduction in headache severity from moderate or severe pain to no pain) and whose most bothersome migraine symptom (nausea, light sensitivity or sound sensitivity) stopped two hours after treatment were significantly greater among patients receiving ubrogepant (19–21% depending on the dose) compared to those receiving placebo (12%). Patients were allowed to take their usual acute treatment of migraine at least two hours after taking ubrogepant. 23% of patients were taking a preventive medication for migraine.
In December 2019, the U.S. Food and Drug Administration approved its medical use. It was the first medication in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine in the USA.
- "Ubrogepant Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 12 August 2021.
- "Ubrelvy- ubrogepant tablet". DailyMed. Archived from the original on 4 June 2021. Retrieved 4 June 2021.
- "FDA approves new treatment for adults with migraine". U.S. Food and Drug Administration (FDA) (Press release). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019. This article incorporates text from this source, which is in the public domain.
- "Ubrogepant (Ubrelvy) Use During Pregnancy". Drugs.com. Archived from the original on 5 March 2021. Retrieved 12 August 2021.
- Scott, LJ (February 2020). "Ubrogepant: First Approval". Drugs. 80 (3): 323–328. doi:10.1007/s40265-020-01264-5. PMID 32020557.
- "Ubrogepant Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 12 August 2021.
- "Ubrogepant". SPS - Specialist Pharmacy Service. Archived from the original on 27 August 2021. Retrieved 13 August 2021.
- Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A (December 2019). "Ubrogepant for the Treatment of Migraine". The New England Journal of Medicine. 381 (23): 2230–2241. doi:10.1056/NEJMoa1813049. PMID 31800988.
- Maddipatla M (23 December 2019). "Allergan's acute migraine treatment wins U.S. FDA approval". Reuters. Archived from the original on 23 December 2019. Retrieved 24 December 2019.
- "Ubrogepant". Drug Information Portal. United States National Library of Medicine. Archived from the original on 2 May 2021. Retrieved 9 July 2021.
- "Drug Trials Snapshots: Ubrelvy". U.S. Food and Drug Administration (FDA). 13 January 2020. Archived from the original on 3 August 2021. Retrieved 9 July 2021.